Rebound of cyst number following discontinuation of guanabenz treatment for latent toxoplasmosis

Mol Biochem Parasitol. 2021 Sep:245:111411. doi: 10.1016/j.molbiopara.2021.111411. Epub 2021 Sep 4.

Abstract

Toxoplasma gondii is a protozoan parasite that causes opportunistic infection in immunocompromised individuals. The parasite forms latent tissue cysts that are refractory to current treatments and give rise to life-threatening reactivated infection following immune suppression. Previously, we showed that guanabenz sharply reduces brain cyst count in BALB/c mice harboring latent toxoplasmosis; however, whether cyst count would change once drug treatment stopped was not addressed. In the present study, we observed a rebound in brain cysts following the discontinuation of guanabenz or a guanabenz-pyrimethamine combination therapy. The re-expansion of brain cysts was not accompanied by symptoms of acute toxoplasmosis. We also tested whether the rebound in cyst counts could be ameliorated by administering pyrimethamine during or after guanabenz treatment.

Keywords: Anti-infective drugs; Guanabenz; Host-pathogen interactions; Parasites; Toxoplasma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Guanabenz* / therapeutic use
  • Mice
  • Mice, Inbred BALB C
  • Recurrence
  • Toxoplasma*
  • Toxoplasmosis* / drug therapy

Substances

  • Guanabenz